Adverse clinical side effects of levodopa therapy.
D000978:Antiparkinson Agents / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001545:Benserazide / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004295:Dihydroxyphenylalanine / Q000009:adverse effects* / Q000652:urine; D004487:Edema / Q000139:chemically induced; D004700:Endocrine System Diseases / Q000139:chemically induced; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D007989:Libido / Q000187:drug effects; D009069:Movement Disorders / Q000139:chemically induced; D009203:Myocardial Infarction / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009461:Neurologic Manifestations; D012119:Respiration / Q000187:drug effects; D013997:Time Factors; D014527:Uric Acid / Q000097:blood; D014555:Urination Disorders / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000978:Antiparkinson Agents; D006834:Hydrazines; D014527:Uric Acid; D004295:Dihydroxyphenylalanine; D001545:Benserazide; D002262:Carboxy-Lyases